- Home
- DMII vs AQST Comparison
DMII vs AQST Comparison
Compare DMII & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
N/A
Current Price
$4.05
Company Overview
Basic Information| Metric | DMII | AQST |
|---|---|---|
| Founded | 2024 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.1M | 529.4M |
| IPO Year | 2025 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DMII | AQST |
|---|---|---|
| Price | $10.19 | $4.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 252.4K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $14.58 |
| Revenue Next Year | N/A | $32.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $9.87 | $2.94 |
| 52 Week High | $10.33 | $6.93 |
Technical Indicators
Market Signals| Indicator | DMII | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 38.90 |
| Support Level | $10.15 | $4.03 |
| Resistance Level | $10.21 | $4.35 |
| Average True Range (ATR) | 0.01 | 0.24 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 66.67 | 29.06 |
Price Performance
Historical Comparison DMII
AQST
About DMII Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp is a blank check Company.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.